Results(4586)
Characterize infections and outcomes developed in relapsed/refractory multiple myeloma (RRMM) patients treated with Teclistamab (SPOT)
Portugal
EU PAS number:
EUPAS1000000414
First published:
10/02/2026
Study
Ongoing
Post-authorisation safety study (PASS): observational cohort study of PAH patients newly treated with either UPTRAVI (selexipag) or any other PAH-specific therapy, in clinical practice (EXPOSURE)
Austria
Belgium
Canada
Czechia
Denmark
Estonia
Finland
France
Germany
Greece
Ireland
Italy
Lithuania
Netherlands
Poland
Portugal
Russian Federation
Slovakia
Spain
Sweden
Switzerland
United Kingdom
EU PAS number:
EUPAS19085
First published:
10/02/2026
Study
Ongoing
GO-First: Real-world treatment patterns and effectiveness outcomes associated with gemtuzumab ozogamicin in first-line Acute Myeloid Leukaemia
Austria
Belgium
Germany
EU PAS number:
EUPAS49268
First published:
10/02/2026
Study
Finalised
A global evaluation of the economic impact of time to initiation of biologic treatment of severe asthma patients
Argentina
Australia
Belgium
Bulgaria
Canada
Colombia
Denmark
Estonia
Greece
India
Ireland
Italy
Japan
Korea, Republic of
Kuwait
Mexico
Norway
Poland
Portugal
Saudi Arabia
Singapore
Spain
Sweden
Taiwan
United Arab Emirates
United Kingdom
United States
EU PAS number:
EUPAS1000000332
First published:
09/02/2026
Study
Finalised
A Retrospective and prospective, obsErvational (non-interventional), post-authorization Safety cohort sTudy to evaluate the incidence of the breAkages and insertion/Removal complications of buprenorphine implants in rouTine clinical care (RE-START)
Italy
EU PAS number:
EUPAS1000000092
First published:
09/02/2026
Study
Discontinued
A multinational Post-Authorisation Safety Study evaluating real-world treatment in patients receiving Yselty® (linzagolix choline) for moderate to severe symptoms of uterine fibroids - DAISY
Germany
Italy
Poland
Spain
United Kingdom
EU PAS number:
EUPAS1000000924
First published:
09/02/2026
Study
Planned
A Study to Assess the Amount of Palopegteriparatide in Breast Milk of Lactating Females Requiring YORVIPATH® (Palopegteriparatide)
United States
EU PAS number:
EUPAS1000000922
First published:
09/02/2026
Study
Planned
A Global Pregnancy Registry to Assess Maternal, Fetal, and Infant Outcomes Following Exposure to YORVIPATH® (Palopegteriparatide) During Pregnancy and Breastfeeding
United States
EU PAS number:
EUPAS1000000921
First published:
09/02/2026
Study
Planned
European non-interventional post-authorization safety study related to serious cardiovascular events of myocardial infarction and stroke, and all-cause mortality for romosozumab by the EU-ADR Alliance
Denmark
France
Germany
Italy
Netherlands
Spain
United Kingdom
EU PAS number:
EUPAS35881
First published:
06/02/2026
Study
Ongoing
The Incidence and Risk factors for Hypocalcaemia Among Osteoporosis Patients Receiving Romosozumab or Other Antiresorptive Therapy in Japan -- A Retrospective Cohort Study Within the Medical Information Database Network (20190207) (MID-NET)
Japan
EU PAS number:
EUPAS1000000055
First published:
06/02/2026
Study
Planned
European Registries for Rare Endocrine and Bone Conditions
First published:
06/02/2026
Austria
Belgium
Croatia
Cyprus
Czechia
Denmark
Estonia
Finland
France
Germany
Greece
Hungary
Israel
Italy
Latvia
Lithuania
Luxembourg
Netherlands
Norway
Poland
Portugal
Romania
Serbia
Slovakia
Slovenia
Spain
Sweden
Switzerland
Türkiye
Ukraine
United Kingdom
United Kingdom (Northern Ireland)
Data source
Human
Disease registry
The Mycophenolate Pregnancy Registry
United States
EU PAS number:
EUPAS10541
First published:
06/02/2026
Study
Ongoing
Periodic Knowledge, Attitudes, and Behavior (KAB) Survey of Certified Prescribers to Assess Understanding of the Risks with the Prolia Risk Evaluation and Mitigation of Strategy (REMS) (20240121)
United States
EU PAS number:
EUPAS1000000393
First published:
06/02/2026
Study
Ongoing
Prospective Observational Non-interventional Study to Describe Characteristics and Management of Patients With Giant Cell Tumor of Bone Treated With XGEVA and Its Use in Routine Clinical Practice in France (20150360)
France
EU PAS number:
EUPAS21542
First published:
06/02/2026
Study
Ongoing
Description of international collaboration in the area of medicines use and effects in COVID-19 affected pregnancies (CONSIGN-International, CONSIGN meta-analyses))
Belgium
Canada
Denmark
Finland
Germany
Iceland
Italy
Netherlands
Norway
Saudi Arabia
Spain
Sweden
Switzerland
United Kingdom
United States
EU PAS number:
EUPAS40317
First published:
05/02/2026
Study
Finalised
Surveillance Of Emicizumab-Treated Patients: An Analysis of the EUHASS Pharmacovigilance Registry (Emicizumab Pharmacovigilance: EUHASS registry)
Austria
Belgium
Bulgaria
Cyprus
Czechia
Denmark
Finland
France
Germany
Greece
Hungary
Ireland
Italy
Latvia
Lithuania
Malta
Netherlands
Poland
Portugal
Romania
Russian Federation
Slovakia
Slovenia
Spain
Sweden
Switzerland
Türkiye
United Kingdom
EU PAS number:
EUPAS23177
First published:
05/02/2026
Study
Ongoing
Real World Evaluation of Sotorasib among Chinese Non-Small Cell Lung Cancer Patients (20240175)
China
EU PAS number:
EUPAS1000000636
First published:
05/02/2026
Study
Ongoing
Évaluation médico-économique, comparative en vie réelle de la morbi-mortalité post-traitement par résection endoscopique par DISsection sous muqueuse vers COlectomie dans le traitement des grandes lésions coliques superficielles en France (DISCO)
France
EU PAS number:
EUPAS1000000919
First published:
05/02/2026
Study
Planned
Post-marketing study to assess the risk of intussusception after immunization with GlaxoSmithKline (GSK) Biologicals’ oral live-attenuated human rotavirus vaccine in infants less than 1 year old in Latin America (212329)
Argentina
Colombia
Dominican Republic
Honduras
Mexico
Panama
EU PAS number:
EUPAS1000000701
First published:
05/02/2026
Study
Ongoing
Baricitinib Drug Utilisation Study: Assessment of Effectiveness of New Recommendations for Use Based on Secondary Data Sources in France, Germany, The Netherlands, and Sweden (I4V-MC-B038)
France
Germany
Netherlands
Sweden
EU PAS number:
EUPAS104431
First published:
05/02/2026
Study
Ongoing
Real World Use, Effectiveness and Safety of Romosozumab among Osteoporosis Patients in Guangdong China (20250009)
China
EU PAS number:
EUPAS1000000758
First published:
05/02/2026
Study
Planned
PASS TachoSil Evaluation (PasTel): Short- and long-term safety evaluation of TachoSil in paediatric population
Poland
EU PAS number:
EUPAS1000000505
First published:
05/02/2026
Study
Planned
Molecular profiling of tissue samples from patients who received a Kite-manufactured gene-modified cell therapy and have developed a secondary malignancy of T-cell origin
European Union
United Kingdom
EU PAS number:
EUPAS1000000769
First published:
05/02/2026
Study
Planned
A Retrospective Cohort Study to Assess Drug Utilisation and Long-Term Safety of Galcanezumab in US Patients in the Course of Routine Clinical Care (I5Q-MC-B001)
United States
EU PAS number:
EUPAS27597
First published:
03/02/2026
Study
Ongoing
Remibrutinib in real-world clinical practice: a prospective, multi-country, non-interventional, effectiveness and safety study (REASSERT)
Canada
China
Germany
Italy
Japan
Korea, Republic of
Spain
United States
EU PAS number:
EUPAS1000000889
First published:
03/02/2026
Study
Ongoing
Post-Authorisation Safety Study (PASS) to Evaluate the Risk of Malignancies in Patients with Myasthenia Gravis (MG) Treated with Efgartigimod
France
United Kingdom
United States
EU PAS number:
EUPAS1000000915
First published:
03/02/2026
Study
Planned
CROSSROADS-1: Treatment Outcomes among Tezspire Users: A Claims Data Study (20230159)
United States
EU PAS number:
EUPAS1000000062
First published:
03/02/2026
Study
Ongoing
CROSSROADS-2: Clinical Characteristics, Treatment Patterns, and Treatment Outcomes Among Users of Tezspire: An Electronic Medical Record (EMR) study (20220066)
United States
EU PAS number:
EUPAS1000000053
First published:
03/02/2026
Study
Ongoing
Real-world hospital treatment patterns in Belgium in early lung cancer between 2018 and 2023: a secondary data analysis [BE-LUNG]
Belgium
EU PAS number:
EUPAS1000000397
First published:
03/02/2026
Study
Finalised
Real-World Molecular Subtypes and Characteristics of Breast Cancer in Belgium: Insights from Routinely Collected Data [BE-REAST]
Belgium
EU PAS number:
EUPAS1000000398
First published:
03/02/2026
Study
Finalised
Leveraging Digital Technology and Artificial Intelligence to Describe the Real World Belgian Chronic Lymphocytic Leukemia Patient Population [BE-CLLEAR]
Belgium
EU PAS number:
EUPAS1000000394
First published:
03/02/2026
Study
Finalised
Real-world disease, patient characteristics and treatment patterns in patients with Non-Small Cell Lung Cancer and extensive stage Small cell lung cancer in Belgium [AIBED]
Belgium
EU PAS number:
EUPAS1000000396
First published:
03/02/2026
Study
Finalised
OTEZLA® tablets General use-results survey (BCT) (20200279)
Japan
EU PAS number:
EUPAS36072
First published:
03/02/2026
Study
Finalised
Evaluating the benefits of RSV maternal vaccination using a Scottish National Dataset. (BORLAND)
United Kingdom
EU PAS number:
EUPAS1000000706
First published:
03/02/2026
Study
Planned
A Post-Authorisation Safety Study (PASS) of ABRYSVO (Respiratory Syncytial Virus Stabilised Prefusion Subunit Vaccine) in Pregnant Women and their Offspring in a Real World Setting in Europe and UK (C3671026)
Denmark
France
Netherlands
Norway
Spain
United Kingdom
EU PAS number:
EUPAS1000000399
First published:
03/02/2026
Study
Ongoing
Registry to Document Treatment Effectiveness, Safety, Including Prospective Long-term Outcomes in Participants with Progressive Familial Intrahepatic Cholestasis (PFIC) who take Odevixibat (Bylvay)
Korea, Republic of
EU PAS number:
EUPAS1000000679
First published:
03/02/2026
Study
Ongoing
DARWIN EU® - RR Characterisation of individuals with cystic fibrosis in Europe
France
Hungary
Italy
Norway
Spain
EU PAS number:
EUPAS1000000710
First published:
03/02/2026
Study
Finalised
DARWIN EU® - Drug utilisation study in individuals with cystic fibrosis in Europe
France
Germany
Italy
Norway
Spain
United Kingdom
EU PAS number:
EUPAS1000000708
First published:
03/02/2026
Study
Ongoing
Real-World Effects and Utilisation Patterns of Elexacaftor, Tezacaftor, and Ivacaftor Combination Therapy (ELX/TEZ/IVA) in Patients with Cystic Fibrosis (CF)
Germany
United States
EU PAS number:
EUPAS43022
First published:
02/02/2026
Study
Ongoing
Post-Approval Observational Cohort Study to Evaluate the Safety of the COMIRNATY 2023-2024 Formula in the United States
United States
EU PAS number:
EUPAS108135
First published:
30/01/2026
Study
Ongoing
Compare data sources